Search

Background: Proliferating trichilemmal tumors (PTTs) are rare benign neoplasms that arise from the outer sheath of a hair follicle. Group III PTTs are high-grade malignant tumors reported to exhibit a high recurrence rate, lymph nodes, and a tendency to develop distant metastasis. Case Presentation: A 25 years old female patient was presented to us with a history of recurring soft tissue scalp lesions. The lesion recurred three times within 1 year. There was no history of trauma. Every time the lesion was excised but no histopathology of the specimen was done. Upon the third recurrence, it came out to be a malignant proliferating trichilemmal tumor (MPTT). Considering the young age of the patient and keeping in view the history of multiple recurrences with positive deep margin even after the third surgery, the patient was planned external beam radiotherapy (RT) 50 Gy/25 fx to scalp with 9 Mev electron using 0.5 cm bolus. The post-RT follow-up currently of 2 years is uneventful. Conclusion: The mainstay of treatment is surgery with wide surgical margins as local recurrence is most common in MPTT. Adjuvant RT was used in this case to prevent recurrence. [ABSTRACT FROM AUTHOR]

Objective Methotrexate (MTx) is an anticancer agent used in the treatment of various cancers. The objective of this study was to document the biodistribution of 99mTc-labelled Mtx (99mTc-MTx) in normal subjects and patients with breast cancers. Methods We prepared the 99mTc-MTx kit by a direct labelling method and studied its biodistribution in volunteer subjects and patients with breast carcinoma breast. This clinical study was preceded by animal trials [1]. Results The normal biodistribution pattern in humans was characterized by nonspecific uptake in the body with the 99mTc-MTx behaving like a blood pool agent with no evidence of specific organ uptake. The kidneys were seen to be the main route of excretion. Biodistribution data of patients with carcinoma breast showed excellent tracer uptake in the tumour and showed no other nonspecific tracer uptake. Conclusion This initial clinical trial showed that 99mTc-labelled anticancer drug can be successfully used for tumour scintigraphy, which appears to be a major breakthrough as this method of labelling and scanning may be useful in future tumour staging, calculating the sensitivity of tumours to certain anticancer agent and response evaluation during chemotherapy. [ABSTRACT FROM AUTHOR]

Objective Methotrexate (MTx) is an anticancer agent used in the treatment of various cancers. The objective of this study was to document the biodistribution of 99mTclabelled Mtx (99mTc-MTx) in normal subjects and patients with breast cancers. Methods We prepared the (99mTc-MTx kit by a direct labelling method and studied its biodistribution in volunteer subjects and patients with breast carcinoma breast. This clinical study was preceded by animal trials [1]. Results The normal biodistribution pattern in humans was characterized by nonspecific uptake in the body with the (99mTc-MTx behaving like a blood pool agent with no evidence of specific organ uptake. The kidneys were seen to be the main route of excretion. Biodistribution data of patients with carcinoma breast showed excellent tracer uptake in the tumour and showed no other nonspecific tracer uptake. Conclusion This initial clinical trial showed that 99mTclabelled anticancer drug can be successfully used for tumour scintigraphy, which appears to be a major breakthrough as this method of labelling and scanning may be useful in future tumour staging, calculating the sensitivity of tumours to certain anticancer agent and response evaluation during chemotherapy. [ABSTRACT FROM AUTHOR]